Table: Sumitomo Pharma -9-MTH group results (IFRS)

Sumitomo Pharma

31/01/2024 06:30

Jan 31 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 9 months ended      9 months ended        Year to   
                Dec 31, 2023        Dec 31, 2022       Mar 31, 2024  
                   LATEST             YEAR-AGO           COMPANY     
                   RESULTS             RESULT            FORECAST    
  Sales            235.03              460.27             317.00     
                 (-48.9 pct)         (+6.5 pct)        (-42.9 pct)   
  Operating      loss 117.75         loss 17.78        loss 156.00   
  Pretax
  Net            loss 117.71         loss 18.50        loss 141.00   
  EPS Basic    loss 296.28 yen     loss 46.57 yen    loss 354.90 yen 
  Ann Div                             21.00 yen            NIL       
  -Q2 Div            NIL              14.00 yen                      
  -Q4 Div                             7.00 yen             NIL       
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T